Hormonal
Effective obesity medications (e.g., GLP-1/GIP agonists) work by lowering the adipose mass set point through counteracting adaptive hormonal responses, allowing homeostasis at a lower weight, but require lifelong use to maintain this new set point.
Obesity medications are not a temporary fix but a long-term management tool for a chronic disease. They work by resetting your body's biological 'thermostat' to a lower weight. If you stop taking them, your biology will fight to regain the weight. Therefore, these medications should be viewed as lifelong treatments, similar to blood pressure medication, to maintain your health.
By counteracting the adaptive response by the brain in response to the changes in gut hormone levels and reduction in leptin levels, obesity medications allow for homeostatic adipose mass regulation at a lower calorie intake and adipose mass set point [65–67]. This is not a permanent resetting, as medication discontinuation has consistently shown return of hunger and adipose mass regain [68, 69].
Why this rating
Supported by preclinical and clinical data reviews cited in the text.
Source
Metabolic and appetitive regulation of adipocyte mass during treatment of obesity
Jonathan Q. Purnell et al. · Journal of Internal Medicine · 2025
DOI 10.1111/joim.70045
More from this paper
- Lifestyle interventions (caloric restriction and exercise) alone are ineffective for long-term obesity treatment because they trigger potent homeostatic adaptive responses (metabolic, hormonal, and appetitive) that defend a higher adipose mass set point and inevitably lead to weight regain.Good
- Metabolic adaptation during weight loss involves a 15-20% reduction in daily energy expenditure beyond what is expected from mass loss, which persists until the previous weight is regained.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →